Dimensional Fund Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.3M | Buy |
379,541
+102,729
| +37% | +$3.45M | ﹤0.01% | 2251 |
|
|
2025
Q4 | $11.9M | Buy |
276,812
+67,425
| +32% | +$2.54M | ﹤0.01% | 2226 |
|
|
2025
Q3 | $5.93M | Buy |
209,387
+54,366
| +35% | +$1.63M | ﹤0.01% | 2491 |
|
|
2025
Q2 | $2.9M | Buy |
155,021
+89,721
| +137% | +$1.7M | ﹤0.01% | 2661 |
|
|
2025
Q1 | $1.17M | Buy |
65,300
+48,177
| +281% | +$977K | ﹤0.01% | 2849 |
|
|
2024
Q4 | $288K | Buy |
+17,123
| New | +$328K | ﹤0.01% | 3118 |
|
|
2022
Q3 | – | Sell |
-28,769
| Closed | -$325K | – | 3516 |
|
|
2022
Q2 | $325K | Sell |
28,769
-118,739
| -80% | -$2.38M | ﹤0.01% | 3164 |
|
|
2022
Q1 | $4.41M | Sell |
147,508
-25,828
| -15% | -$699K | ﹤0.01% | 2572 |
|
|
2021
Q4 | $4.59M | Buy |
173,336
+7,140
| +4% | +$215K | ﹤0.01% | 2585 |
|
|
2021
Q3 | $6.03M | Buy |
166,196
+93,701
| +129% | +$3.69M | ﹤0.01% | 2527 |
|
|
2021
Q2 | $3.15M | Sell |
72,495
-116,370
| -62% | -$4.39M | ﹤0.01% | 2734 |
|
|
2021
Q1 | $6.46M | Sell |
188,865
-15,749
| -8% | -$624K | ﹤0.01% | 2485 |
|
|
2020
Q4 | $7.16M | Sell |
204,614
-4,809
| -2% | -$139K | ﹤0.01% | 2394 |
|
|
2020
Q3 | $5.03M | Buy |
209,423
+1,517
| +0.7% | +$37.2K | ﹤0.01% | 2444 |
|
|
2020
Q2 | $3.81M | Sell |
207,906
-18,765
| -8% | -$338K | ﹤0.01% | 2573 |
|
|
2020
Q1 | $3.54M | Sell |
226,671
-16,876
| -7% | -$359K | ﹤0.01% | 2528 |
|
|
2019
Q4 | $5.21M | Sell |
243,547
-25,960
| -10% | -$534K | ﹤0.01% | 2595 |
|
|
2019
Q3 | $5.04M | Buy |
269,507
+2,028
| +0.8% | +$41.9K | ﹤0.01% | 2594 |
|
|
2019
Q2 | $6.98M | Buy |
267,479
+49,485
| +23% | +$1.12M | ﹤0.01% | 2539 |
|
|
2019
Q1 | $5.6M | Buy |
217,994
+54,991
| +34% | +$1.26M | ﹤0.01% | 2612 |
|
|
2018
Q4 | $3.75M | Buy |
163,003
+116,669
| +252% | +$3.29M | ﹤0.01% | 2688 |
|
|
2018
Q3 | $1.49M | Buy |
+46,334
| New | +$1.39M | ﹤0.01% | 2984 |
|
|
2018
Q2 | – | Sell |
-19,204
| Closed | -$680K | – | 3375 |
|
|
2018
Q1 | $680K | Hold |
19,204
| – | – | ﹤0.01% | 3066 |
|
|
2017
Q4 | $745K | Sell |
19,204
-2,000
| -9% | -$76.1K | ﹤0.01% | 3041 |
|
|
2017
Q3 | $538K | Sell |
21,204
-8,895
| -30% | -$216K | ﹤0.01% | 3096 |
|
|
2017
Q2 | $822K | Sell |
30,099
-72,211
| -71% | -$1.98M | ﹤0.01% | 3018 |
|
|
2017
Q1 | $3.39M | Sell |
102,310
-16,534
| -14% | -$421K | ﹤0.01% | 2692 |
|
|
2016
Q4 | $2.83M | Sell |
118,844
-24,388
| -17% | -$699K | ﹤0.01% | 2721 |
|
|
2016
Q3 | $5.26M | Sell |
143,232
-2,193
| -2% | -$62.9K | ﹤0.01% | 2496 |
|
|
2016
Q2 | $3.24M | Sell |
145,425
-7,302
| -5% | -$182K | ﹤0.01% | 2633 |
|
|
2016
Q1 | $3.18M | Sell |
152,727
-9,355
| -6% | -$231K | ﹤0.01% | 2639 |
|
|
2015
Q4 | $4.91M | Sell |
162,082
-20,404
| -11% | -$619K | ﹤0.01% | 2522 |
|
|
2015
Q3 | $4.51M | Buy |
182,486
+20,004
| +12% | +$597K | ﹤0.01% | 2560 |
|
|
2015
Q2 | $5.21M | Buy |
162,482
+506
| +0.3% | +$19.3K | ﹤0.01% | 2567 |
|
|
2015
Q1 | $5.78M | Buy |
161,976
+16,771
| +12% | +$460K | ﹤0.01% | 2503 |
|
|
2014
Q4 | $3.3M | Sell |
145,205
-8,048
| -5% | -$163K | ﹤0.01% | 2709 |
|
|
2014
Q3 | $2.97M | Buy |
153,253
+8,146
| +6% | +$230K | ﹤0.01% | 2721 |
|
|
2014
Q2 | $5.27M | Buy |
145,107
+45,199
| +45% | +$1.54M | ﹤0.01% | 2549 |
|
|
2014
Q1 | $3.88M | Sell |
99,908
-18,705
| -16% | -$667K | ﹤0.01% | 2645 |
|
|
2013
Q4 | $3.38M | Buy |
118,613
+16,419
| +16% | +$482K | ﹤0.01% | 2708 |
|
|
2013
Q3 | $3.66M | Buy |
102,194
+16,471
| +19% | +$601K | ﹤0.01% | 2669 |
|
|
2013
Q2 | $2.86M | Buy |
+85,723
| New | +$3.88M | ﹤0.01% | 2704 |
|
Other funds holding RIGL
AC
VCM
Dimensional Fund Advisors's RIGL Position: Q1 2026 in Review
Dimensional Fund Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 37% in Q1 2026, buying an estimated $3.45M and bringing the position to 379,541 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2251.
Dimensional Fund Advisors first reported a position in RIGL in Q2 2013 and has held it in 42 quarters since. The position peaked at $11.9M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Dimensional Fund Advisors held 379,541 shares of Rigel Pharmaceuticals worth $10.3M as of Q1 2026.
- Dimensional Fund Advisors bought 102,729 Rigel Pharmaceuticals shares in Q1 2026, an estimated $3.45M.
- Rigel Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2251 holding.
- Dimensional Fund Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
- Dimensional Fund Advisors's Rigel Pharmaceuticals position peaked at $11.9M in Q4 2025.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.